The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

In Brief

Pelotonia awards six grants to Ohio State

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

PELOTONIA awarded six, two-year grants to projects at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital & Richard J. Solove Research Institute.

Pelotonia is a fundraising bicycle tour established in 2009 to raise money for cancer research at Ohio State. In the past four years, 67 OSUCCC – James research teams have received Pelotonia Idea Grants. A total of $650,000 will be awarded in this latest round of grants, with $6.6 million in funding awarded since the program’s inception.

The 2014 Pelotonia Idea Grants funded the following projects: Identifying and Developing New Immunoagents for Cancer Diagnosis and Therapy; Proteasomal Pathway Regulates PTEN Protein Degradation and Promotes Carcinogenesis; A Mass-Spectrometry Approach to Mapping Histone Modification Crosstalk; Develop IL-27 Based Combinational Immunotherapy of Cancer; Ceragenin-based Therapy for Multiple Myeloma; and Defining the Role of Autophagy in Anoikis Resistance and in Peritoneal Carcinomatosis/Sarcomatosis.

Table of Contents

YOU MAY BE INTERESTED IN

Regulatory News

Makary vows to speed up drug approvals and end FDA’s “cozy” relationship with industry
Commissioner promises to protect scientific integrity while bringing in “fresh” MAHA ideas

In his first sit-down interview since beginning his role as FDA commissioner 17 days earlier, Marty Makary, a former Johns Hopkins surgeon and the only Trump pick for HHS whose confirmation received Democratic support, said he would speed up approvals for rare-disease treatments by reducing reliance on animal testing and shifting towards organoids and computational models. 
By Claire Marie Porter
Guest Editorial

Regulation must keep up with scientific advances

The American Cancer Society’s recent report on the increasing incidence rates of colorectal cancer in young adults once again rang an alarm bell for adults over 45 to get checked, especially if they are having symptoms. But as an oncologist with more than 40 years of experience, I also believe that this should be a clarion call to scientists and researchers, and for regulators at the FDA.
By Richard M. Goldberg
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account